Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein RBD (Omicron B.1.1.529 Variant) Antibody from ABBEXA LTD
Search, find, compare suppliers for anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein RBD (Omicron B.1.1.529 Variant) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein RBD (Omicron B.1.1.529 Variant) |
| Clone | monoclonal |
| Host Species | Recombinant Human |
| Reactive Species | n/a |
| Isotype | IgG1 kappa |
| Format | affinity purified |
| Size | 100 µg, 1 mg, |
| Concentration | 3.64 mg/ml |
| Applications | ELISA, WB |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Spike Protein RBD (Omicron B.1.1.529 Variant) Neutralizing antibody is a recombinant Human monoclonal antibody expressed in CHO cells against SARS-CoV-2/COVID-19 Spike Protein RBD (Omicron B.1.1.529 Variant). The SARS-CoV-2 Spike Protein (S protein) is a viral protein that allows the entry of SARS-CoV-2 into human cells. The protein forms trimers on the viral capsid and binds to human Angiotensin Converting Enzyme 2 (ACE2) located on the cell surface. The protein has a cleavage site between the S1 and S2 subunits that is targeted by the human enzyme Furin, and it may also cause the development of a syncytium (cell fusion). Antibodies to S protein can prevent viral entry as well as target the virus for further immune action. The B.1.1.529 (Omicron) variant was identified in South Africa in November 2021. It possess a large number of mutations which appear to increase the risk of reinfection compared to other variants of concern. |
| Immunogen | SARS-CoV-2 |
| Other Names | Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV-2, COVID-19, 2019-nCoV, 2019 novel coronavirus, COVID19, Severe Acute Respiratory Syndrome Coronavirus 2, Severe Acute Respiratory Syndrome Coronavirus 2, Severe Acute Respiratory Syndrome Coronavirus 2 , Severe Acute Respiratory Syndrome Coronavirus 2 , SARS-CoV-2, SARS-CoV-2, SARS-CoV-2 , SARS-CoV-2 , COVID-19, COVID-19, COVID-19 , COVID-19 , 2019-nCoV, 2019-nCoV, 2019-nCoV , 2019-nCoV , 2019 novel coronavirus, 2019 novel coronavirus, 2019 novel coronavirus , 2019 novel coronavirus , COVID19, COVID19, COVID19 , COVID19 |
| Gene, Accession # | n/a |
| Catalog # | abx376490 |
| Price | please inquire |
| Order / More Info | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein RBD (Omicron B.1.1.529 Variant) Antibody from ABBEXA LTD |
| Product Specific References | n/a |
ABBEXA LTD
ABBEXA LTD
181 Cambridge Science Park
Cambridge, CB4 0GJ UK
P: +44 (0) 1223 755950
Customer Service: info@abbexa.com
Technical Support: support@abbexa.com
Orders: orders@abbexa.com
https://www.abbexa.com
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950
Profile of ABBEXA LTD
Return to Antibodies